Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22314138 | 0.76 | PPARG (0.33) | PPARGPPARA | |
| SCHEMBL5559452 | 0.72 | PPARG (0.39) | PPARGPPARA | |
| SCHEMBL25086443 | 0.71 | ELANE (0.31) | — | |
| SCHEMBL5558215 | 0.69 | KDM4E (0.51) | PPARGPPARA | |
| SCHEMBL10212104 | 0.66 | ELANE (0.35) | — | |
| SCHEMBL10227005 | 0.65 | ELANE (0.34) | — | |
| SCHEMBL16817568 | 0.64 | — | — | |
| SCHEMBL18999252 | 0.64 | PPARG (0.36) | PPARGPPARA | |
| SCHEMBL10808054 | 0.64 | TP53 (0.30) | — | |
| SCHEMBL21721647 | 0.63 | ELANE (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1572203-B1 | SUBSTITUTED 4-ALKOXYOXAZOL DERIVATIVES AS PPAR AGONISTS | HOFFMANN LA ROCHE (CH) | 2007-11-07 | — | — | EP | disclosed |
| US-7109225-B2 | Antidiabetic agents; hypotensive agents; anticholesterol agents; antilipemic agents; antiinflammatory agents; antiproliferative agents | HOFMANN-LA ROCHE INC. (US) | 2006-09-19 | — | — | US | disclosed |
| EP-1572203-A1 | SUBSTITUTED 4-ALKOXYOXAZOL DERIVATIVES AS PPAR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-09-14 | — | — | EP | disclosed |
| US-20040157898-A1 | Novel substituted oxazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2004-08-12 | — | — | US | disclosed |
| WO-2004041275-A1 | SUBSTITUTED 4-ALKOXYOXAZOL DERIVATIVES AS PPAR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157898-A1 | Novel substituted oxazole derivatives | OXA1L, SLC5A1, GPR119 | PPARG 400/4885PPARA 497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.